PeptideLabs Logo
PeptideLabs
All profiles

Selank + Semax

Non-standardised blend · Blends & catalogue terms

Linked in communities to stress and cognition claims; clinical benefit and safety of the blend are unproven.

Not FDA/EMA approved
LibraryNo account · this device only

Also known as: SK + XA · Selank/Semax blend

Use at a glance

Selank + Semax

Linked in communities to stress and cognition claims; clinical benefit and safety of the blend are unproven.

Which entry would you like to view?

Choose a source entry. Different products and study groups do not form one combined plan.

Online report · not medically verified

What amount?
Selank 250–500 µg
How often?
once per day
What time of day?
morning
What period?
Week 1
How is it used?
Identify every ingredient and its amount first. The same blend name can refer to different products.
Does it need mixing?
Without individual amounts and joint stability data there is no verified recipe. Correct arithmetic does not establish compatibility.
View preparationCheck sources
Overview of all entries

  • Selank + Semax · Week 1

    Online report · not medically verified

    Selank 250–500 µg · once per day · morning

  • Selank + Semax · Week 2+

    Online report · not medically verified

    Semax 300–800 µg + Selank 250–500 µg · once per day + once per day · morning, before 2 pm per source

  • Selank + Semax · intranasal reports

    Online report · not medically verified

    Semax 400–600 µg + Selank 400–750 µg · 2 times per day + 2–3 times per day · morning / midday

  • Selank + Semax · cycle / pause

    Online report · not medically verified

    — · 10–14 days / ≤8 weeks · not reliably established

More factsNon-standardised blend · Blends & catalogue terms
Classification
Non-standardised blend · Blends & catalogue terms
Research focus
Linked in communities to stress and cognition claims; clinical benefit and safety of the blend are unproven.
Evidence
Anecdotal
Status
Not FDA/EMA approved

This entry is not a single peptide, or its use depends on diagnosis, product form or composition. A blanket peptide dose would be misleading.

Schedule explained in detailNo uniform peptide protocol

Amount status

The reference describes separate community products, not a validated blend: intranasal Semax 200–300 µg twice daily and Selank 200–250 µg two to three times daily; not a recommendation.

Profile evidence level: anecdotal.

Timing

It states Selank 15–30 minutes first, then Semax in the morning/early afternoon. This sequence is not clinically confirmed.

No individual recommendation.

Cycle/duration

Commonly cited short cycles: 10–14 days intranasal; subcutaneous community plans reach up to eight weeks. No combination study.

No individual recommendation.

External community reference availableThe external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Mixing & calculations

Without individual amounts and joint stability data there is no verified recipe. Correct arithmetic does not establish compatibility.

Ratio-specific blend calculator

For the selected explicitly stated composition, this calculates total and per-component amounts for a U-100 draw. The ratio remains fixed to the chosen example.

The calculation uses final volume, which is not automatically the amount of water added. Excipients can change the volume; a concentration specified by the manufacturer takes priority.

Assumed composition

10 mg Semax

Separate vials

This example concerns separate vials. Components are calculated individually and must not be interpreted as a pre-blended product.

Documented calculation points

What the selected U-100 amount contains mathematically

Semax: 300 µg

More calculation values

Total concentration

3.333 mg/ml

Volume

0.09 ml

Total amount in draw

300 µg

Calculated draws

33.3

Concentration per component

Semax: 3.333 mg/ml

Calculation aid only, not dosage, reconstitution or use advice. Use only when identity, each component amount and the ratio are independently confirmed. U-100 means 100 units per ml; other syringe scales are not interchangeable.

Complete ratio and U-100 examplesEach row applies only to the stated composition and assumed final volume. A different ratio produces different component amounts.

Semax · 10 mg · 3 ml

9 U

Semax: 300 µg

Assumed final solution volume
3 ml
Volume
0.09 ml
Total amount in draw
300 µg

Semax · 10 mg · 3 ml

15 U

Semax: 500 µg

Assumed final solution volume
3 ml
Volume
0.15 ml
Total amount in draw
500 µg

Semax · 10 mg · 3 ml

18 U

Semax: 600 µg

Assumed final solution volume
3 ml
Volume
0.18 ml
Total amount in draw
600 µg

Semax · 10 mg · 3 ml

24 U

Semax: 800 µg

Assumed final solution volume
3 ml
Volume
0.24 ml
Total amount in draw
800 µg

Semax · 10 mg · 2 ml

6 U

Semax: 300 µg

Assumed final solution volume
2 ml
Volume
0.06 ml
Total amount in draw
300 µg

Semax · 10 mg · 2 ml

10 U

Semax: 500 µg

Assumed final solution volume
2 ml
Volume
0.1 ml
Total amount in draw
500 µg

Semax · 10 mg · 2 ml

12 U

Semax: 600 µg

Assumed final solution volume
2 ml
Volume
0.12 ml
Total amount in draw
600 µg

Semax · 10 mg · 2 ml

16 U

Semax: 800 µg

Assumed final solution volume
2 ml
Volume
0.16 ml
Total amount in draw
800 µg

Selank · 10 mg · 3 ml

7.5 U

Selank: 250 µg

Assumed final solution volume
3 ml
Volume
0.075 ml
Total amount in draw
250 µg

Selank · 10 mg · 3 ml

12 U

Selank: 400 µg

Assumed final solution volume
3 ml
Volume
0.12 ml
Total amount in draw
400 µg

Selank · 10 mg · 3 ml

15 U

Selank: 500 µg

Assumed final solution volume
3 ml
Volume
0.15 ml
Total amount in draw
500 µg

Selank · 10 mg · 2 ml

5 U

Selank: 250 µg

Assumed final solution volume
2 ml
Volume
0.05 ml
Total amount in draw
250 µg

Selank · 10 mg · 2 ml

8 U

Selank: 400 µg

Assumed final solution volume
2 ml
Volume
0.08 ml
Total amount in draw
400 µg

Selank · 10 mg · 2 ml

10 U

Selank: 500 µg

Assumed final solution volume
2 ml
Volume
0.1 ml
Total amount in draw
500 µg
All preparation informationProduct details and calculation examples from the available sources.

No blend U-100 conversion without a confirmed ratio and route. A single-substance example from the reference — Selank 10 mg +2 ml, 250 µg =5 U — must not be transferred to a mixture.

Reconstitution & quantitiesOpen basics, units and sources
Explained in very simple termsBefore reading any number: this page reports what a product label, study or online community states. It does not say what any person should use.

Amount

mg or µg describe the mass of a substance. That is not the same as ml of fluid or U on a syringe. The number is only the amount stated by the identified source.

Interval

The interval only describes the time stated between two points. For example, once every 7 days does not mean daily and never justifies catching up or doubling.

Cycle

A cycle is a stated period that may include breaks. A community cycle proves neither effectiveness nor safety and does not prevent long-term risks.

Reconstitution

Reconstitution means mixing powder with a defined volume of fluid. This changes concentration, not the total amount in the vial. On U-100, 100 U equals exactly 1 ml of volume.

Not a guide to misuse

All community figures are shown only to place widely circulated online protocols in context. They are not instructions for self-use, injection, performance enhancement or any other misuse. Approved figures apply only to the exact named product, approved indication and medical supervision.

Research, risks & more detailsMechanism, adverse effects, storage, comparisons and common questions.

Mechanism: what is supported and what does not follow

Non-standardised blend of two experimental neuropeptides

Selank + Semax is classified as “Non-standardised blend of two experimental neuropeptides”. Linked in communities to stress and cognition claims; clinical benefit and safety of the blend are unproven. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

Neuropeptide blend

This studies how two individually experimental peptides acting on the nervous system are marketed together by vendors, similar to combining two separate tools into a set without testing them together. Studies mostly look at the individual substances, not the combination.

02

Anxiolytic signalling

This studies how a peptide affects stress and anxiety responses in animal models, similar to observing whether an animal stays calmer in an unfamiliar environment. Behavioural tests and stress hormone levels are measured.

03

Neuroprotective signalling

This examines whether a substance can protect nerve cells from stress or damage, such as after oxygen deprivation in a cell model. Cell survival and signalling markers in nerve tissue under lab conditions are measured.

What communities discuss

These themes describe discussions and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Stack and blend discussion

Users exchange self-assembled combinations of several peptides and compare perceived effects, often without the specific combination ever having been studied. Such stack recommendations are personal opinions, not vetted protocols.

Nootropic forums

Subjective effects on concentration, mood, or stress perception after taking experimental neuropeptides are discussed, often based on personal journals. Such self-reported impressions are strongly influenced by expectation and do not replace controlled studies.

Vendor marketing claims

Vendors often advertise products with broad efficacy claims, comparison tables against competitors, and customer quotes. Such marketing statements are driven by sales interest and do not constitute independent scientific proof of efficacy.

Adverse effects and safety risks

  • Blends combine not only possible effects but also uncertainty, interactions, dosing errors and stability problems. An effect cannot be assigned reliably to one component.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Do not self-use / obtain clinical review

  • No use should be inferred without full qualitative and quantitative composition, batch testing and stability data; every comorbidity and medicine adds concern.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • No validated monitoring exists for non-standardised blends. Individual lab values cannot make an unknown composition or interaction safe.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Anecdotal

Clinical benefit and safety of the blend are unproven.

Clinical evidence

Claims rely mostly on personal experience reports and vendor statements rather than controlled studies.

This combination pairs two individually experimental neuropeptides; the blend is additionally not standardised.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and common errors

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Not FDA/EMA approved

No FDA- or EMA-approved medicinal product; efficacy and safety are not established.

WADA 2026

The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile